You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / NATCO PHARMA

NATCO PHARMA
Intrinsic Value | Fundamental Analysis

Returns | 1W : -1.4% , 1M : 1.1%,1Y : 51%
BOM : 524816     NSE : NATCOPHARM    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward
Pledged Shares : None or < 25%
May 14,2021
Price(EOD): Rs. 928.30
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
MarketCap: Rs. 16,922.91 Cr
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
NATCO PHARMA -1.4% 1.1% 51%
SUN PHARMACEUTICAL INDUSTRIES 1.7% 11.6% 51.5%
DR REDDYS LABORATORIES 0.4% 4.1% 40.6%
DIVIS LABORATORIES -0.2% 6.3% 71.8%
CIPLA 2.4% 0.1% 57.7%
BIOCON 2.1% -3.8% 12.2%
AUROBINDO PHARMA -0.6% 9.9% 47.1%
LUPIN -1.4% 12.7% 42.7%
TORRENT PHARMACEUTICALS 4.1% 6.5% 11.5%


FUNDAMENTAL ANALYSIS OF NATCO PHARMA

 
Fundamentals Score
[Last Annual Data : Mar2020 | TTM
Trailing Twelve Months (TTM) is calculated using last 4 quarterly data and is a good substitute to track Annual results.
Learn More
]
Show Me the Stocks with Fundamentals better than NATCO PHARMA Premium


VALUATION OF NATCO PHARMA

 
Valuation Score
Ratio Standalone
P/E
P/B
P/S
35.61
P/E Calculated based on EPS of 26.07
[ Mar2020 - Standalone Results ]

4.39
P/B Calculated based on Book Value of 211.31
[ Mar2020 - Standalone Results ]

9.11
P/S Calculated based on Revenues of 1857.7 Cr
[ TTM - Standalone Results ]

Show Me the Stocks with Valuation better than NATCO PHARMA Premium


FAIR VALUE OF NATCO PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
114%
35%
37%

SHARE PRICE MOMENTUM OF NATCO PHARMA

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2020
2019
2018
Avg_3yrs
0.08
0.11
0.06
0.08
0.08
0.11
0.06
0.08
[Last Annual Data : Mar2020]

PLEDGED SHARES

Pledged Shares
0 %
As on : Mar2021

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Standalone Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-30.9%
-13.5%
-18.27%
-22.85%
-26.09%
-38.28%
-44.46%
-47.2%
QtrlyTrend
-8
Latest Qtr: Dec2020

NATCO PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE 0.2% 6.8% 61%
S&P BSE MIDSMALLCAP -0.3% 6.2% 97.6%
S&P BSE 400 MIDSMALLCAP -0.4% 6.1% 98.4%
S&P BSE MID CAP -0.5% 4.3% 81.8%
S&P BSE ALLCAP -0.7% 4% 68.7%
S&P BSE 500 -0.7% 3.8% 67.2%
S&P BSE LARGE MIDCAP -0.7% 3.4% 63%
S&P BSE 200 -0.8% 3.5% 64.2%
S&P BSE 250 LARGEMIDCAP -0.8% 3.5% 64.6%
S&P BSE MOMENTUM -0.9% 4.7% 40.8%
S&P BSE 150 MIDCAP -0.9% 5.1% 90.8%
NSE Indices1W1M1Y
NIFTY MID SMALL400 -0.3% 6.2% 99.8%
NIFTY MIDCAP150 -0.7% 4.9% 90.7%
NIFTY 500 -0.7% 3.7% 66.7%
NIFTY FREE MIDCAP 100 -0.7% 5.4% 94%
NIFTY LARGE MIDCAP 250 -0.8% 4% 74.5%
NIFTY 200 -0.8% 3.4% 63.1%

FAQ [Frequently Asked Questions]


Is NATCOPHARM good for long term investment?

As on 14-May-2021, the Fundamentals of NATCOPHARM are Strong and hence it's good for long term investment! See Financial Performance of NATCO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is NATCOPHARM UnderValued or OverValued?

As on 14-May-2021, NATCOPHARM is Over Valued and hence NOT a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of NATCOPHARM ?

As on 14-May-2021, the Intrinsic Value of NATCOPHARM is Rs. 677.66 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 434.52
Fair Value [Median EV / Sales Model] : Rs. 686.05
Fair Value [Median Price / Sales Model] : Rs. 677.66
Median Fair Value of NATCOPHARM : Rs. 677.66

Is NATCOPHARM trading at a Premium or Discount?

As on 14-May-2021, NATCOPHARM is trading at a Premium of 37% based on the Median Intrinsic Value!

Is it right time to buy NATCOPHARM shares?

As on 14-May-2021, NATCOPHARM is Over Valued and hence NOT a good buying opportunity according to Share Valuation at this time!

What is the Financial Performance of Industry Peers of NATCOPHARM?

Check out Financials of Industry Peers using below links:
Financials of SUN PHARMACEUTICAL INDUSTRIES LTD
Financials of DR REDDYS LABORATORIES LTD
Financials of DIVIS LABORATORIES LTD
Financials of CIPLA LTD
Financials of BIOCON LTD
Financials of AUROBINDO PHARMA LTD
Financials of LUPIN LTD
Financials of TORRENT PHARMACEUTICALS LTD
Financials of CADILA HEALTHCARE LTD
Financials of ABBOTT INDIA LTD

What are the Frequent Comparisons with NATCOPHARM?

NATCO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DR REDDYS LABORATORIES LTD
NATCO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD
NATCO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD
NATCO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs BIOCON LTD
NATCO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs AUROBINDO PHARMA LTD
NATCO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs LUPIN LTD
NATCO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs TORRENT PHARMACEUTICALS LTD
NATCO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CADILA HEALTHCARE LTD
NATCO PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs ABBOTT INDIA LTD

Open Demat Account & Start Investing
    Affiliate Links

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z